Trial Information

Official Title: Ribavirin Pregnancy Registry

Summary

Ribavirin should be avoided during pregnancy and during the 6 months before pregnancy in both the female and the male sexual partner. If a pregnancy occurs and is reported to the Ribavirin Pregnancy Registry, the Registry will follow the pregnant woman throughout pregnancy. The Registry will also follow the infant until 1 year of age. The goal of the Registry is to learn more about the effects of ribavirin on pregnancy and the risk for birth defects. Pregnant women exposed to ribavirin, either by taking ribavirin (during pregnancy or 6 months before pregnancy) or through a male sexual partner (who took ribavirin during the female partner's pregnancy or during the 6 months before pregnancy), are encouraged to contact the Registry.

Phase: Phase 4

Sponsor: INC Research

Overall Contacts:

Cathy Ryan
800 593 2214
pregnancyregistries@incresearch.com

Stacey Stone
Phone: 800 593 2214
pregnancyregistries@incresearch.com